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Summary A retrospective study was undertaken to evaluate terminal transferase activity and glucocorticoid
receptor content as predictors of prognosis in 52 adult patients with acute myeloid leukemia (AML). Eighteen
patients who had detectable levels of TdT in their leukaemic cells (O.1unitpg-1 DNA), had a higher
complete remission rate than patients with low TdT activity. Patients below 60 years with increased TdT
activity also had longer survival as compared to those with low TdT levels. By combining cytochemical
analysis of peroxidase and immunocytochemical staining for TdT it was possible to show that the enzyme was located in leukaemic cells of myeloid origin. Leukemias of monocytic origin had no detectable TdT activity in
10/11 cases.
The cellular content of the cytoplasmic glucocorticoid receptor varied from 0 to 2.8 fmol ug- 1 DNA. There
was no difference in receptor content between the different FAB subgroups. High levels of the receptor
(>0.22 fmol pg 1 DNA) were positively correlated with the remission rate.
Patients with TdT levels of .0.1 unit g-1 DNA and a glucocorticoid receptor concentration of
.0.22fmolpg-1 DNA had significantly higher remission (P=0.001) and survival rates (P=0.007) compared
with those with undectectable levels of both TdT and low receptor content.
It is thus concluded that combined measurements of TdT and the glucocorticoid receptor are useful
predictors ofprognosis in AML.
By the use of morphology and cytochemistry AML
can be subclassified into six groups according to the
FAB classification (Bennet et al., 1976). In most
protocols, however, all six subclasses are given the
same type of chemotherapy and there appear to be
only marginal differences in prognosis between the
subclasses and the best prognostic indicator has
been the age of the patient (Keating et al., 1980).
We have recently described that analysis of the
content of TdT and glucocorticoid receptor in
leukaemic cells adds significant prognostic
information (Skoog et al., 1982).
Terminal transferase (TdT) is an enzyme which
was originally considered to be a specific marker
for lymphoid cells of the T-or pre B-type
(Hoffbrand et al., 1977). AML cells contain in
general low or undetectable levels of the enzyme
but occasional cases of AML cells with elevated
TdT levels have been described (Marcus et al.,
1976; Shrivastava et al., 1976). It has been
suggested that these rare cases are of the same
lineage as the primitive lymphoid cells and thus are
not true AML cases. This cellular specificity of TdT
has been generally accepted and determinations of
the enzyme are done to aid morphological and
cytochemical classification of leukaemic cells. In
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line with this it has been observed that in blast
crisis of chronic myelogenous leukaemia,
responsiveness to ALL-treatment (vincristine and
prednisone) is confined to patients whose leukaemic
cells are transferase positive (Marks' et al., 1978).
We have recently reported that several patients with
cytochemically verified AML have a low but
detectable TdT activity. Such patients had a higher
remission and survival rate as compared to those
with no detectable TdT activity in their blast cells
(Skoog et al., 1982). This finding was of particular
interest since it was the first time that a biochemical
parameter with prognostic implications was
described for AML.
It was long ago realized that patients with ALL
usually respond to glucocorticoid therapy (Shanbrom, 1962; Childrens Cancer Study Group,
1967). In the case of AML conflicting results have
been reported. Approximately 10-15% of the
patients responded to glucocorticoid therapy while
some patients showed progression on the same
therapy (Knospe & Conrad, 1966). Thus steroids
have not been widely accepted for the treatment of
AML.
We know that glucocorticoids, like other steroids,
require the binding to a specific receptor to exert its
action. Binding of glucocorticoids to such receptors
has been detected both in intact cells and cytosol
from normal and leukaemic cells (Bell, 1982).444 L. SKOOG et al.
Measurements of the cellular receptor content in
ALL have shown that there is a positive correlation
between receptor level and response to treatment
with steroids (Lippman et al., 1978). Furthermore
there are indications that the receptor levels in ALL
represent a prognostic variable which to some
extent is independent of the immunological
phenotype. Patients with high receptor content in
their leukaemic cells had a long remission
contrasting those with low receptor levels who had
a shorter remission duration (Lippman et al., 1978).
In the case of AML the receptor level, as
determined by whole cell assay, does not appear to
be related to survival or response to chemotherapy
(Bell, 1982). However, in a recent study we reported
that there exists a positive correlation between
cellular cytosol receptor content and survival in
AML (Skoog et al., 1982).
The present paper extends our previous study of
TdT and glucocorticoid receptor as prognostic
indicators in AML.
Material and methods
Patients
We have studied 52 adult patients with acute
myeloid leukemia (AML). Peripheral blood was
collected before therapy was started. All the
patients were treated according to the protocol of
the Leukaemia Group of Central Sweden (LCS).
Thirty patients were less than 60 years old and were
treated with daunorubicin and cytarabine initially
and if complete remission could be established they
were given courses of either daunorubicin and
cytarabine or cytarabine and thioguanine as
maintenance therapy. Twenty-two patients were 60
years or older, and received a somewhat milder
initial treatment with thioguanine and cytarabine. A
few elderly patients were treated with prednimustine
(LEO, Sweden) as well.
Criteriafor diagnosis. Classification
Our criteria for the diagnosis acute leukaemia were
the findings of .50 percent leukaemic cells in the
bone marrow or an unequivocal finding of Auer
rods. The classification was made according to the
FAB classification (Bennet et al., 1976) with slight
modifications (Ost et al., 1983).
Cytochemical methods used for classification, the
procedure for isolation of leukaemic cells from
peripheral blood and measurements of TdT activity
have been published previously (Skoog et al., 1983).
Glucocorticoid receptor determinations
Ficoll-Isopaque purified blast cells (>2 x 107) were
homogenized in 0.5ml of ET buffer (lOmM Tris-
HCl, pH7.4, 1.5mM EDTA) containing 10%
glycerol (v/v), ImM dithiotreitol and 50nM
1.2 (n) x [3H]-dexamethasone (Amersham
25Cinmole-1). After homogenization the mixture
was incubated at 4°C for 30min and then
centrifuged at 15.000g for 20min at 4°C. The pellet
was used for DNA determination as described by
Burton (1968). Unbound steroid was removed by
treatment with dextran coated charcoal and
trypsinized as outlined elsewhere (Wrang et al.,
1981). The receptor - [3H]-dexamethasone complex
was isolated by isoelectric focusing in slabs of
polyacrylamide gel as prebiously described (Wrang
et al., 1981). The receptor - [3H]-dexamethasone
complex focused at pH 5.8.
Immunofluorescent staining ofcells in suspension
The following monoclonal antibodies were used for
phenotypic characterization of the leukaemic cells:
J5 against common ALL antigen and B1 against
B-lymphocyte antigen, both kindly provided by Dr
Schlossmann. OKla (HLA class II) (Ortho
Diagnostics, Sweden), OKT3 (mature T-lymphocyte
antigen) (Ortho Diagnostics, Sweden), NA1/34
(human thymocyte antigen) McMichael, Sera Labs,
England), A3/10 (HLA class 1) (Trowbridge) kindly
provided by Dr Trowbridge.
Thirty microliters of appropriately diluted (1/1-
1/5) antibodies were added to 106 pelleted cells and
were incubated for 1 h at 4°C. After washing 3
times, the incubation was repeated with 30p1 of
1/20 diluted fluorescein isothiocyanate-conjugated
F(ab')2 sheep anti-mouse Ig serum preabsorbed
with human serum (Natl. Bact. Lab., Stockholm,
Sweden).
Immunofluorescent staining of TdT
For immunofluorescent staining (IFL) of TdT, two
affinity purified rabbit antisera were used, one was
kindly provided by Dr Bollum and the other was
purchased from PL Biochemical (S.T. Goar, FRG).
The thawed leukaemic cells were Ficoll-Paque
separated prior to cytocentrifugation. The slides
were air-dried, fixed in cold methanol (30min at
4°C) and dehydrated in PBS. Five microliters rabbit
anti-TdT was added and the slides incubated
(30min at 20°C) in a humidified chamber. The
slides were washed in PBS (30min) before repeating
the staining procedure with purified sheep anti-
rabbit Ig labelled with FITC (Natl. Bact. Lab.,
Stockholm, Sweden) for 30min at 200C. After
repeated washing in PBS (30min at 200C), the
slides were sealed in formolglycerol under a
coverslip and examined in a standard Zeiss
microscope with epi-illuminator and 63x oil phase
contrast objective.TdT AND GLUCOCORTICOID RECEPTOR LEVELS AND PROGNOSIS IN AML
Only cells which by phase contract were
considered as blastic or mononuclear were
evaluated, and the frequency of stained nuclei was
scored.
Results
Patients
The mean values of WBC, frequency of Auer rods,
percentage of leukemic cells in peripheral blood and
the bone marrow in the different FAB subclasses
are given in Table I. It can be seen from this table
that 29 cases were classified as acute myeloblastic
leukaemias (M1-2), 23 of which showed some
degree of maturation (M2). The number of
monocytic leukaemias (M5a-M5b) was 11, and the
number of myelomonocytic leukaemias (M4) was
also 11. It can also be seen from this table that
Auer rods were found in 33/52 cases which is in
good agreement with observations from a
consecutive series at S6dersjukhuset, Stockholm
(Ost et al., 1982). The finding of Auer rods was not
correlated to an increased remission or survival
rate.
Complete remission was achieved in 22 of the
patients (42.3%). The complete remission rate of
the patients <60 years old was 56.7% compared to
22.7% for patients over 60 years. The complete
remission rate and the survival rate of the two
groups differed significantly (P=0.014 and P=0.09,
respectively). There was no significant difference in
either complete remission rate or survival time
between the FAB subclasses or between leukaemias
with or without Auer rods.
Terminal deoxynucleoteodyl transpherase
The activity of TdT in AML cells is generally
undetectable or low and high levels of the enzyme
have been interpreted to mean a lymphocytic origin
of the leukaemic cells. We found measurable
activity of TdT (ranging from 0.02 to
7.84units jg-1 DNA) in 24 patients with
cytochemically verified AML. In the remaining 28
patients no activity could be detected
[<0.01 unitug-1 DNA). The mean value for all
cases was 0.52units ug- 1 DNA. Figure 1 depicts
the logarithmic values for the TdT activity within
the different FAB groups, and it can be seen from
this figure that the "pure" myeloid leukemias (Ml, M2) contained higher levels of enzyme activity than
the monocytic subclasses (M5a+M5b).
We have previously shown that a high cellular
level (.0.10unitspg-1 DNA) of TdT is positively
correlated to response to treatment. In accordance
with this we found that patients below 60 years
with a TdT value equal or above 0.10unitpg-1 DNA had a higher complete remission rate (10/12)
than patients with values lower than 0.10unitpg-1 DNA (7/18) P=0.016. This was also true if the M5
cases, which in general have low TdT levels, were
excluded. The survival time was 540 days for
patients with high TdT values as compared to 120
days for those with low values (P=0.010). No
correlation was found between age and TdT level.
Among the patients who went into complete remission a survival time of 630 days was observed
for those with a high TdT content in their blasts as
compared to 363 days for those with a low TdT
content. This difference is not statistically significant, which is probably explained by the low
number ofpatients in each group.
IFL staining ofTdT
Biochemical determinations of TdT give a mean
value for a large number of leukaemic cells. It is
thus possible that the moderately elevated levels
observed in the Ml, M2 cases could result from a
contamination with lymphoid cells. To analyse this
we selected four cases of AML with increased levels
of TdT as measured biochemically and performed
an IFL staining of TdT. One case of myeloblastic
Table I FAB-diagnoses, Auer rods, WBC and percentage of leukaemic cells in peripheral blood and bone marrow
% ofleukaemic
WBC cells in the % ofleukaemic cells
Cases with mean value (range) peripheral blood in the bone marrow FAB-diagnoses No (%) Auer rods J09-1 mean value (range) mean value (range)
ml 6 (11.5) 2 52 (2-128) 75 (25-95) 86 (64-98)
M2 23 (44.2) 18 83 (13-170) 80 (54-99) 83 (60-97) M4 11 (21.2) 9 69 (5-269) 64 (20-97) 71 (44-95) M5a 3 (5.8) 1 137 (40-310) 98 (98-99) 95 (94-96) M5b 8 (15.4) 3 76 (35-145) 74 (30-95) 80 (62-94) M6 1 (1.9) 0 40 47 55
Total 52 (100) 33
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Figure 1 TdT values in different FAB subclasses.
leukaemia without maturation (M1) showed a
positive nuclear staining for TdT in 50% of the
cells; the biochemically determined value was
1.75units g-1 DNA. The percentage of cells
showing peroxidase positivity was 95%. A case of
M2 had a TdT activity of 7.84units,ug- DNA
with 62% of peroxidase positive cells and 85% of
the cells showed positive nuclear staining for TdT
with the immunofluorescense method. Only 5% of
the cells were J5-positive and 1% of the cells were
positive for OKT3.
Similar results were observed for two other cases
of Ml-M2. It thus appears to be clear from these
results that the enzyme TdT is found in the
leukaemic myeloid cells since the majority of the
cells showed positivity both for peroxidase and
TdT.
Glucocorticoid receptor
We have previously described that AML cells
contain varying amounts of the cytoplasmic
receptor for glucocorticoids. In the 52 AML cases
now tested the glucocorticoid receptor levels ranged
from 0 to 2.8fmoljug-1 DNA. The content of the
glucocorticoid receptor was not significantly
correlated to the age of the patients. The mean and
median value was 0.31 and 0.22fmol4ug-1 DNA,
respectively. Figure 2 summarizes the glucocorticoid
receptor content within the different FAB
subclasses and we were unable to detect any
differences in glucocorticoid receptor content
between the groups. Correlations of the cellular
levels of glucocorticoid receptor to remission rate
and stirvival showed that patients (all ages) with a
high content of glucocorticoid receptor
(.0.22 fmolyg-1 DNA) in their leukaemic cells'
had a complete remission rate of 57% while only
25% of those with a low receptor content
(<0.22fmol g-1 DNA) responded. This difference
is significant with a P value of 0.019. We were
unable to find such a difference between the
receptor rich and poor groups if patients under or
over 60 years were analyzed separately. Moreover
no statistically significant differences was observed
concerning time of survival.
Prognostic significance of combined glucocorticoid
receptor levels and TdT values
The cellular level of TdT and the glucocorticoid
receptor were not correlated with each other
(P=0.30). Since both parameters were shown to
give prognostic information it was of interest to
analyse if their usefulness as predictors of prognosis
could be increased if they were combined.
Among the 52 patients studied 10 had both an
increased glucocorticoid receptor content
(.0.22fmolyg-1 DNA) and TdT activity
(. 0.1 unit ug 1 DNA. Nine of these patients went
into complete remission upon therapy. In the group
of 16 patients with receptor poor and TdT poor
cells only 4 (25%) achieved complete remission.
These remissions were all confined to M5 cases. Of
the remaining 12 patients 8 survived for more than
30 days and were given an adequate therapeutic
trials.
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Figure 2 Glucocorticoid receptor values in different FAB subclasses.
The difference in complete remission rate is
statistically significant (P=0.001). There was also a
significant difference (P=0.007) between the two
groups concerning survival as shown in Figure 3.
This difference was also found when patients under
1 )no
-I
.
n3
Time (y)
Figure 3 The survival time of patients with a high
content of TdT (.0.1unitpg-1 DNA) and the
glucocorticoid receptor (.0.22fmolejg-1 DNA) as
compared to that of patients with a low level of
TdT (<0.1 unityg-1 DNA) and the receptor
(<0.22fmoljg-1 DNA). The unbroken line represents
patients with a high TdT and receptor content and the
dotted line those with a low enzyme and receptor level.
60 years were studied (P=0.007). There were only 2
patients over 60 years who had high levels of both
TdT and the glucocorticoid receptor. One of these
patients survived for 759 days while the other one
lived for 2 days. Seven patients over 60 years
showed low values for both the receptor and TdT.
Only 2 of these patients survived for more than 120
days (239 and 157 days respectively). We thus
conclude that a combination of the glucocorticoid
receptor level and TdT content increase their
usefulness as predictors ofprognosis.
Discussion
The material we present in this paper represents a
group of AML cases only. All patients with a
dysmyeloplastic syndrome before diagnosis, ALL
(according to ummunological markers) and one
case of mixed leukaemia (ALL+M4) were
excluded. We are thus convinced that the patients included in the present study are "pure" AML.
cases. It is therefore of interest that 24 of these
"pure" AML had measurable activity of TdT in
their leukaemic cells. It should be noted that the
level of TdT was considerably lower (1/10-1/100) than that observed in ALL cells and cells from
some blast crisis of chronic myeloid leukaemias.
Immunofluorescence staining for TdT presented
two important results. Firstly, the enzyme occurs in
the nucleus of myeloid cells. Secondly, it appears that the IFL positivity is evenly distributed among
a fraction of the cells. These findings conclusively
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show that a varying proportion of the leukaemic
cells in some myeloid leukaemias contain TdT,
albeit at a lower level than lymphoid cells.
There are several previous reports on the
prognostic value of TdT determinations in
leukaemia Skoog et al., 1982; Marks et al., 1978;
Mertlesman, 1982; Sasaki et al., 1981). The
majority of these studies have been on cells from
patients with ALL and CML in blast crisis. In such
cases TdT positivity indicates a high rate of
responsiveness to chemotherapy Marks et al., 1978;
Sasaki et al., 1981). In an earlier study of AML we
found that patients whose leukaemic cells have an
increased level of TdT have both higher remission
and survival rates (Skoog et al., 1982). The number
of patients was, however, small aid it was therefore
of interest to confirm our findings on a larger
group ofpatients.
The present article confirms that AML patients
(<60 years) with high cellular levels of the enzyme
have a significantly higher remission rate than those
with low levels. These results are in contrast to
those reported by Mertelsman (1982) who found
that increased levels of TdT was correlated to a low
remission rate and a shorter survival. In the latter
study TdT positivity was defined in a
semiquantitative way whereas our results are based
on absolute values. This may partly explain the
discrepancies observed although the biochemical
background remains to be explored.
Mertelsman (1982) also described that the
presence of Auer rods in TdT negative patients was
associated with an increased remission rate. In our
material we were unable to attach any prognostic
information to the finding ofAuer rods.
There are several reports on the presence of
glucocorticoid receptors in normal and neoplastic
lymphoid and myeloid cells as well as in
erythropoietic cells. In ALL high receptor levels
appeared to be a prognostic favourable sign
(Lippman et al., 1978; Sasaki et al., 1981). In the
case of AML conflicting results have been
presented. Bell (1982) who measured the receptor in
intact cells could not find any correlation between
prognosis and receptor levels. In contract to this we
have previously shown that a high level of the
glucocorticoid receptor, when measured in the
cellular cytosol, was positively correlated to the
remission rate as well as survival. The present study
shows that patients having a receptor level equal or
above 0.22fmol ug-1 DNA have a significantly
higher complete remission rate than patients with a
low receptor value. However, we could not observe
any difference in length of survival or length of first
complete remission between the receptor rich and
receptor poor groups in this material. At present we
are unable to explain the discrepancies beween the
results obtained with whole cell measurements and
those based on cytosol receptor determinations. It
could be speculated that the receptor values as
determined by the whole cell technique depend not
only on the amount of free cytosol receptor but
also on the rate of translocation of the steroid-
receptor complex into the nucleus and rate of
degradation. No translocation or degradation
occurred with the technique for receptor
determination used in this paper.
Unfortunately there are no antibodies available
to the glucocorticoid receptor and it is thus not
possible to show conclusively that the receptor as
measured biochemically is located in all the
leukaemic cells. When such antibodies are available
it will be interesting to study the inter-and
intracellular distribution in the leukaemic cells.
The levels of TdT and the glucocorticoid receptor
may represent separate prognostic parameters.
Thus, by combining both variables it was possible
to show that patients with high levels of both TdT
and the receptor had significantly higher remission
rate and longer survival time as compared to those
with low values of TdT and the receptor. A similar
finding has been reported for patients with ALL
and CML in blast crisis (Sasaki et al., 1981). It is
of interest to note that the remission rate and
survival time did not correlate to other variables
such as WBC, FAB subclass and the finding of
Auer rods in our material. Although it is hard to
explain the basis for prognostic prediction using
TdT and the glucocorticoid receptor it is of
importance to report such results since there are
few good prognostic indicators in AML. It is
possible that determinations of TdT and the
glucocorticoid receptor can be of importance when
planning new therapeutic strategies in the future.
Furthermore it seems questionable if patients above
60 years of age with low TdT and low
glucocorticoid receptor levels have any benefit from
cytostatic drugs in the combinations and doses used
in this series.
The results presented in this paper further stress
the great heterogeneity of the AML which is a
challenging field for future research.
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